# Moderna, Inc. (MRNA) FY2024 Q3 Balance Sheet

- Company: Moderna, Inc. (MRNA)
- Period: As of 2024-09-30
- Filing: Q3 FY2024 10-Q, filed 2024-11-07, accession number 0001682852-24-000060
- Page: https://plicit.ai/financials/mrna/fy2024-q3-balance-sheet
- Chart image: https://plicit.ai/charts/mrna-fy2024-q3-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2024-09-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 15,803,000,000 US dollars
- **Current assets**: 9,666,000,000 US dollars
- **Non-current assets**: 6,137,000,000 US dollars
- **Liabilities**: 3,876,000,000 US dollars
- **Current liabilities**: 2,201,000,000 US dollars
- **Non-current liabilities**: 1,675,000,000 US dollars
- **Equity**: 11,927,000,000 US dollars
- **Investments**: 5,223,000,000 US dollars
- **Cash and cash equivalents**: 1,644,000,000 US dollars
- **Accounts receivable, net**: 1,564,000,000 US dollars
- **Prepaid expenses and other current assets**: 823,000,000 US dollars
- **Inventory**: 412,000,000 US dollars
- **Property, plant and equipment, net**: 2,381,000,000 US dollars
- **Investments, non-current**: 2,335,000,000 US dollars
- **Right-of-use assets, operating leases**: 784,000,000 US dollars
- **Other non-current assets**: 556,000,000 US dollars
- **Deferred tax assets**: 81,000,000 US dollars
- **Accrued liabilities**: 1,376,000,000 US dollars
- **Deferred revenue**: 379,000,000 US dollars
- **Accounts payable**: 373,000,000 US dollars
- **Other current liabilities**: 69,000,000 US dollars
- **Income taxes payable**: 4,000,000 US dollars
- **Operating lease liabilities, non-current**: 679,000,000 US dollars
- **Financing lease liabilities, non-current**: 625,000,000 US dollars
- **Other non-current liabilities**: 276,000,000 US dollars
- **Deferred revenue, non-current**: 95,000,000 US dollars
- **Retained earnings**: 11,165,000,000 US dollars
- **Additional paid-in capital**: 751,000,000 US dollars
- **Accumulated other comprehensive income (loss)**: 11,000,000 US dollars
- **Preferred stock, par value $0.0001; 162 shares authorized as of September 30, 2024 and December 31, 2023; no shares issued or outstanding at September 30, 2024 and December 31, 2023**: 0 US dollars
- **Common stock, par value $0.0001; 1,600 shares authorized as of September 30, 2024 and December 31, 2023; 385 and 382 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively**: 0 US dollars

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.